Region
Service
Sector
Iktos is a leader in AI and robotics for drug discovery, offering innovative platforms for molecule design and synthesis. Their proprietary solutions, Makya™, Spaya™, and Iktos Robotics, enhance pharmaceutical R&D efficiency. Through strategic collaborations and recent acquisition of Synsight, they integrate cutting-edge chemistry and biology AI to target complex interactions, advancing oncology and immunology pipelines.
Iktos faced PR challenges due to its complex, AI-driven drug discovery technology, which is hard for non-technical audiences to grasp. A lack of public success stories made it difficult to demonstrate tangible benefits, further complicating effective communication. The company operated in a niche market, limiting general public interest and resulting in restricted, inconsistent, and specialized press coverage. These factors combined hindered broader media attention and the clear communication of Iktos's value proposition to a wider audience.
PRLab's strategy for Iktos focused on boosting brand awareness and establishing thought leadership. The approach leveraged Iktos's unique AI and automation to stand out. By creating high-quality content, newsjacking, and showcasing partnerships, PRLab aimed to position Iktos as a leader in biotech. The strategy also emphasized elevating the CEO's profile and targeting niche publications to reach key decision-makers effectively.
PRLab's media research for Iktos started with a deep look into their strengths, weaknesses, opportunities, and threats, especially regarding how they communicate. We also studied how other similar companies get news coverage to find out what worked best. This helped PRLab plan how to make Iktos stand out, focusing on getting them featured in important publications and becoming recognized as a leader in their field.
Iktos's press releases boosted its market presence and credibility, particularly within the AI and biotech fields. The collaboration with Cube Biotech and securing the EIC Accelerator Grant garnered substantial attention. These announcements, widely picked up by European and U.S. business news outlets, along with industry-specific trade media, reached a wide range of audience. This strategic distribution amplified Iktos's brand awareness and solidified its position as a forward-thinking leader in AI-driven solutions.
We focused on elevating Iktos as a prominent voice in AI-driven drug discovery by consistently sharing valuable insights and demonstrating expertise. This involves actively participating in industry conversations and leveraging the team's knowledge to become sought-after by the media. Our goal was to build credibility and establish Iktos as an influential authority, ensuring global visibility, especially among investors.
Iktos had mention growth directly attributable to PR activities. In addition to these efforts, Iktos experienced organic growth in its Share of Voice through incidental coverage. This type of coverage, while not directly secured by PRLab, often resulted from placements we obtained and could include citations in industry articles, passing mentions, or inclusions in roundups and quotes. This incidental coverage was crucial for building credibility, reinforcing brand awareness, and maintaining Iktos's presence in relevant conversations. This contributed to 84.44% of brand mentions originating from news sources over the first six months, signaling successful PR performance.
143.2m Estimated audience || 8.8k Engagement Rates || 2 Incidental Publications
Over the past six months, our PR collaboration with Iktos boosted their brand visibility and credibility. We secured widespread media coverage on high-authority news sites, reaching a potential audience of over 143 million and generating 8.8k engagements. Press releases proved effective, contributing to a measurable increase in Iktos' share of voice against competitors.
